Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference at 3:30 p.m. ET on May 19, 2026.
A live webcast and replay will be available via the company’s investor relations website.
Details
News Market Reaction – MCRB
On May 12, the day this news came out, MCRB closed 1.53% above the previous close.
Data tracked by StockTitan Argus for the May 12 session.
Key Figures
- Conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference
- Presentation time
- 3:30 p.m. ET
- Company overview presentation at investor conference
Historical Context
-
Reported Q1 2026 net loss and limited cash runway to Q3 2026.
-
Presented supportive SER-603 preclinical data at DDW 2026.
-
Showcased SER-155 Phase 1b and translational data at ESCMID Global.
-
Announced participation in CARB-X Investor Day with platform overview.
-
Reported FY 2025 net income and cash of $45.8M with runway to Q3 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
live biotherapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m. ET on May 19, 2026.
A live webcast of the presentation will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at http://www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics, with a focus on inflammatory and immune diseases. The Company led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, which has received Breakthrough Therapy and Fast Track designations, is being advanced for patients undergoing allogeneic hematopoietic stem cell transplant, and is Phase 2 ready, pending receipt of funding. An investigator-sponsored trial of SER-155 is ongoing in immune checkpoint inhibitor–related enterocolitis to further evaluate the potential breadth of the Company’s live biotherapeutic platform. SER-603, in development for inflammatory bowel disease, is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity by targeting inflammatory bacteria and associated metabolites. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.